Advertisement

Topics

Companies Related to "Ablynx Rejects Novo Nordisk Billion Acquisition Proposal" [Most Relevant Company Matches] RSS

09:58 EDT 21st July 2018 | BioPortfolio

Here are the most relevant search results for "Ablynx Rejects Novo Nordisk Billion Acquisition Proposal" found in our extensive corporate database of over 50,000 company records.

Showing "Ablynx Rejects Novo Nordisk Billion Acquisition Proposal" Companies 1–25 of 1,600+

Extremely Relevant

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic succ...


Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed and independently operating companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established to manage the Foundation's funds and to invest actively in other companies. We invest in companies th...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What makes Novo A/S different from other holding companies and venture capital firms is its expertise in commercialising science, taking a long-term responsibility and investing solely in sustainable solutions...


Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufac...

Novo Nordisk Inc.

Novo Nordisk Canada Inc.

Team Novo Nordisk

Relevant

Ablynx nv

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies™ therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and h...

Ferrosan A/S

As a consequence of a re-evaluation of the parent company's strategies, Novo Nordisk decided at the end of 1994 to focus on its core activities - diabetes care and hormone replacement therapy. Other activities, among these being Ferrosan, were put up for sale. 1995Management buy-out In November 1995, Ferrosan changed ownership through a management buy-out. Ferrosan A/S was taken over by the Fer...

Michigan Citizens Against Unrestricted Science and Experimentation

"This proposal is deliberately deceptive. Lawyers and politicians intentionally drafted this language to mislead the voters. This proposal will allow unregulated and unrestricted experimentation on human embryos.

NOVO Engineering

NOVO engineering (www.NOVOengineering.com) is a leading privately held design engineering firm whose team of world-class engineers has been exceeding clients’ needs since 1997. Since its inception NOVO has been helping companies to generate paradigm-shifting new products, commercialize new technology, overcome resource constraints, provide specific te...

NOVO 1

Since 1987, NOVO 1 has been dedicated to tailoring contact center solutions to support clients’ business goals in building customer relationships and growing their brands. NOVO 1′s Customer Obsession Program™ and Smart Desktop Solutions™ incorporate game-changing technology and top 1% industry best-practices to design customized solutio...

National Changing Diabetes Program

The National Changing Diabetes® Program (NCDP) is a multi-faceted initiative that brings together leaders in diabetes and policy to improve the lives of people with diabetes. NCDP strives to create change in the U.S. health care system to provide dramatic improvement in the prevention and care of diabetes. Launched in 2005, NCDP is a program of Novo Nordisk. For more information, please visit ...

Parx Casino Philly Cycling Classic

The Parx Casino Philly Cycling Classic is operated by a community-based non-profit organization formed to organize and host the new world-class professional cycling race in Philadelphia. Joining title sponsor Parx Casino is event Founding Sponsor New Penn Financial, and official sponsors Novo Nordisk, Philadelphia Federal Credit Union, Fuji Bikes, Amstel R...

DANSK BIOTEK

DANSK BIOTEK (The Danish Association of Biotechnology Industries) works to improve conditions for biotechnological research and production in Denmark, and to further the common interests of members, nationally and internationally. DANSK BIOTEK represents the biotechnological industry within drug development, industry and foods (red, white and green biotechnology) and spans all areas of research, d...

The Randall Group, LLC

The Randall Group is a small privately held company formed exclusively to assist advanced technology companies obtain funding through competitive grant opportunities. Our PhilosophyAt The Randall Group, we believe that your proposal's success will not come from having the very best technical plan, or better market data than the other applicants. It won't be assured from having the best writer on s...

Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Bost...

Phase Forward Incorporated

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Sc...

Osprey Pharmaceuticals U.S.A., Inc.

Osprey Pharmaceuticals U.S.A. is focused on the development of protein therapeutics for the treatment of inflammatory and autoimmune conditions based on the company's proprietary therapeutic platform of Leukocyte Population Modulators (LPMs). Osprey Pharmaceuticals U.S.A. is advancing a pipeline of proprietary LPMs, novel fusion protein therapeutics designed to selectively and systematically neutr...

Chemel AB

1996Chemel AB was founded. The main activities involve development, manufacture and marketing of electrochemical analytical instrumentation - SIRE® Biosensor.During 1997The rights to an international patent application (Sensors based on Injection of the Recognition Element, SIRE) were acquired from the European Institute of Science AB (publ). As a result, Chemel AB (priv.) initiated the productio...

ZymoGenetics, Inc.

ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. The company has developed and is marketing RECOTHROM® Thrombin, topical (Recombinant) in the United States. ZymoGenetics has two product candidates in Phase 2 clinical development: PEG-Interferon lambd...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To date, Domantis has raised a total of $83M, most recently attracting additional $29 million in a Series B prime venture financing in December 2005 from new investors Novo Nordisk and MC Life Science Ventu...

De Novo Pharmaceuticals Ltd

The volume of structural protein data that will emerge in the next few years will serve as a driver that transforms the pharmaceutical industry. Over the next decade it is predicted that the high-resolution 3-D structure of all proteins that precisely define the biological space of human, pathogenic organisms and plant proteomes will be available. As this flood of data on proteins becomes availabl...

The Goodglick Company

The Goodglick Company, established in 1956, is a progressive commercial/industrial real estate organization dedicated to alert service. The firm rejects the status quo while driven to searching out new goals and directions, preserving long standing relationships and creating new ones.The staff is highly motivated by the excitement inherent in planning for the future, acting thereupon, and accompli...

De Novo Pharmaceuticals

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment round in April 2000, followed by a second round of funding of £16.75 million in July 2001. Investors in the first round included Avlar Bioventures, Prelude Technology and Cambridge Research and Innovati...


More From BioPortfolio on "Ablynx Rejects Novo Nordisk Billion Acquisition Proposal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks